Using multiple AT products may be the best option for dry eye

Article

A study demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication

A study featured in the European Journal of Ophthalmology has demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication.

Dr Gil Calvão-Santos et al., Ophthalmology Department, Centro Hospitalar de Entre o Duoro e Vouga-Unidade de Santa Maria da Feira, Portugal, split 27 patients with dry eye symptoms into 4 groups. Group A was administered Tears Again, B was given Optive, C received Opticol and D was the control group.

Patients were observed on day 0, 7 and 30 after being administered the AT. Data analysis was conducted, as well as tear break-up time (TBUT), Schirmer tests and Ocular Surface Disease Index.

The findings demonstrated no significant differences between any of the groups. From day 0 to 30 the amount of eyes with abnormal TBUT was reduced. However, eyes presenting with an average TBUT increased in all groups and Schirmer value decreased in groups B, C and D, but increased in group A.

Tear film was recovered in all of the AT groups, but AT targeting just the internal and intermediate layer caused a small decline on lachrymal production. It was suggested that different types of AT should be used on different layers of the eye for the treatment of corneal surface diseases affecting eye lubrication.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.